Immunogenicity and Safety Study of GSK Biologicals' Trivalent Split Virion Influenza Vaccine (GSK1536489A) Fluviral (2012/2013 Season) in Adults Aged 18 Years and Older

Trial Profile

Immunogenicity and Safety Study of GSK Biologicals' Trivalent Split Virion Influenza Vaccine (GSK1536489A) Fluviral (2012/2013 Season) in Adults Aged 18 Years and Older

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2013

At a glance

  • Drugs GSK 1536489A (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 24 Aug 2012 Actual patient number (113) added as reported by ClinicalTrials.gov.
    • 24 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Aug 2012 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top